KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $23,987.88 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $10.02, for a total value of $23,987.88. Following the transaction, the insider now directly owns 102,940 shares of the company’s stock, valued at approximately $1,031,458.80. This represents a 2.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

KalVista Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ KALV opened at $10.69 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The stock has a 50 day moving average of $9.04 and a two-hundred day moving average of $10.35. The stock has a market cap of $528.28 million, a P/E ratio of -2.94 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALV. China Universal Asset Management Co. Ltd. lifted its stake in KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of KalVista Pharmaceuticals by 23.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares during the last quarter. Emerald Advisers LLC raised its stake in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals during the third quarter worth approximately $175,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of KalVista Pharmaceuticals by 114.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 22,949 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 12,245 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).